Eddine Saiah

USPTO Granted Patents = 33 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 133(Granted Patents)

Company Filing History:

Navitor Pharmaceuticals, Inc.

patents

2 out of 8

Raze Therapeutics, Inc.

patents

4. 2 out of 2,076

Janssen Pharmaceutica Nv

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

patents

Years Active: 2009-2025

Loading Chart...

33 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12427130 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2025-09-30),

2. 12378263 - Modulators of sestrin-GATOR2 interaction and uses thereof (2025-08-05),

3. 12202836 - Bicyclic-fused heteroaryl or aryl compounds (2025-01-21),

4. 12187728 - Caffeine inhibitors of MTHFD2 and uses thereof (2025-01-07),

5. 11944605 - Rapamycin analogs and uses thereof (2024-04-02),

6. 11819476 - Rapamycin analogs and uses thereof (2023-11-21),

7. 11702424 - Bicyclic-fused heteroaryl or aryl compounds (2023-07-18),

8. 11679090 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2023-06-20),

9. 11370792 - Caffeine inhibitors of MTHFD2 and uses thereof (2022-06-28),

10. 11339144 - Heteroaryl Rheb inhibitors and uses thereof (2022-05-24),

11. 11325924 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2022-05-10),

12. 11197867 - Aminopyrimidinyl compounds (2021-12-14),

13. 10980815 - Aminopyrimidinyl compounds (2021-04-20),

14. 10980784 - Rapamycin analogs and uses thereof (2021-04-20),

15. 10912750 - Modulators of Sestrin-GATOR2 interaction and uses thereof (2021-02-09),

Title: Eddine Saiah: Innovator in Pharmaceutical Chemistry

Introduction

Eddine Saiah, an accomplished inventor based in Brookline, MA, holds an impressive portfolio of 31 patents. His work primarily focuses on the development of novel compounds with significant pharmaceutical applications. Saiah's contributions to the field of chemistry and medicine have garnered attention from both industry and academia.

Latest Patents

Among Saiah's latest patents are the following notable innovations:

1. **Bicyclic-fused heteroaryl or aryl compounds** - This patent discloses compounds, tautomers, and pharmaceutically acceptable salts featuring a specific structural formula. It underscores the potential for these compounds to be formulated into liquid dosage forms containing therapeutic amounts serving as adjuvants in treating various disorders.

2. **Caffeine inhibitors of MTHFD2** - This invention focuses on compounds and their compositions useful in treating medical conditions. It outlines methods of employing these inhibitors to provide therapeutic benefits, illustrating Saiah's ongoing commitment to innovative healthcare solutions.

Career Highlights

Eddine Saiah's career includes significant tenures at prestigious companies in the pharmaceutical industry. He has worked with Pfizer Corporation, a leading global biopharmaceutical company, and Navitor Pharmaceuticals, Inc., which specializes in developing cancer therapies. His work in these organizations has been pivotal in translating research breakthroughs into practical medical applications.

Collaborations

Throughout his innovative journey, Saiah has collaborated with noteworthy professionals, including David John O'Neill and Seungil Han. These partnerships have allowed him to expand his research capabilities and enhance the impact of his inventions.

Conclusion

Eddine Saiah's extensive patent portfolio and his contributions to pharmaceutical chemistry exemplify a dedicated commitment to advancing medical science through innovation. His latest patents reflect a forward-thinking approach to drug development, making him a significant figure in the realm of medicinal chemistry. As he continues to explore and innovate, Saiah remains an influential inventor shaping the future of healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.